Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 362-364

  Gastaud, Lauris ^a   Ambrosetti, Damien ^a   Otto, Josiane ^a   Marquette, Charles Hugo ^a   Coutts, Michael ^a   Hofman, Paul ^a   Esnault, Vincent ^a,b   Favre, Guillaume ^a,b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

Author keywords

Acute kidney injury; Acute tubular necrosis; Adverse drug reaction; Chemotherapy; Crizotinib; EML4 ALK protein; Non small cell lung carcinoma; Tyrosine kinase inhibitor

Indexed keywords

ALBUMIN; BEVACIZUMAB; CEFTRIAXONE; CISPLATIN; CREATININE; CRIZOTINIB; DOCETAXEL; PEMETREXED;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; ARTICLE; ATELECTASIS; BOWMAN CAPSULE; BRONCHOSCOPY; BRONCHUS OBSTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CYBERKNIFE; DEATH; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL; FATIGUE; FEVER; HEMATURIA; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; LUNG ADENOCARCINOMA; LUNG INFECTION; MALE; MEDIASTINUM LYMPHADENOPATHY; MONONUCLEAR CELL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THORAX RADIOGRAPHY; TRACHEA TUMOR; TREATMENT RESPONSE; URINE SEDIMENT; VOMITING; WEIGHT REDUCTION;

ACUTE KIDNEY INJURY; ACUTE TUBULAR NECROSIS; ADVERSE DRUG REACTION; CHEMOTHERAPY; CRIZOTINIB; EML4-ALK PROTEIN; NON-SMALL-CELL LUNG CARCINOMA; TYROSINE KINASE INHIBITOR;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; TIME FACTORS;

EID: 84887022695     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.007     Document Type: Article

References (17)

1. Lameire N.H., Flombaum C.D., Moreau D., Ronco C. Acute renal failure in cancer patients. Ann Med 2005, 37:13-25.
2. Lameire N., Van Biesen W., Vanholder R. Acute renal failure. Lancet 2005, 365:417-430.
3. Coppo P., Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets 2009, 9:36-50.
4. Bollee G., Patey N., Cazajous G., Robert C., Goujon J.M., Fakhouri F., et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 2009, 24:682-685.
5. Kapiteijn E., Brand A., Kroep J., Gelderblom H. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol 2007, 18:1745-1747.
6. Khurana A. Allergic interstitial nephritis possibly related to sunitinib use. Am J Geriatr Pharmacother 2007, 5:341-344.
7. Winn S.K., Ellis S., Savage P., Sampson S., Marsh J.E. Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect. Nephrol Dial Transplant 2009, 24:673-675.
8. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
9. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
10. Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
11. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J Clin Oncol 2013, 31:1105-1111.
12. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
13. Haase M., Devarajan P., Haase-Fielitz A., Bellomo R., Cruz D.N., Wagener G., et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011, 57:1752-1761.
14. Aapro M., Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 2011, 38:235-240.
15. Michels J., Spano J.P., Brocheriou I., Deray G., Khayat D., Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol 2009, 2:53-56.
16. Jhaveri K.D., Flombaum C.D., Kroog G., Glezerman I.G. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 2011, 117:c312-c319.
17. Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007, 49:186-193.